Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 12, 2016. The document serves as a transaction notification regarding a purchase of company securities by a Person Discharging Managerial Responsibilities (PDMR).
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It is a regulatory disclosure of a specific share transaction.
| Metric | Value |
|---|---|
| Transaction Type | Acquisition of ordinary shares under ShareReward Plan |
| Instrument | Ordinary shares of 25 pence each (ISIN: GB0009252882) |
| Transaction Price | £16.7127 per share |
| Total Volume | 14 Ordinary shares (7 partnership shares + 7 matching shares) |
| Transaction Date | July 11, 2016 (12:18 GMT) |
| Exchange | London Stock Exchange (XLON) |
Material Changes
The filing does not report material changes to the company's financial position or operations compared to prior periods. It solely discloses an insider transaction involving the Chief Financial Officer.
Management Commentary and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. The transaction was executed by Mr. S Dingemans, CFO, under the Company's ShareReward Plan.
Investor Verification Points
- Verify the total number of shares held by Mr. S Dingemans post-transaction to assess insider ownership concentration.
- Confirm the terms of the ShareReward Plan to understand the matching share mechanism utilized in this transaction.
- Note that this filing provides no insight into GSK's broader financial health or operational performance for the period.